Loading
A phase 2 trial of Dronabinol in Breast cancer, run by City of Hope Medical Center, now recruiting.
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors is a phase 2 interventional study registered as NCT06731894 by City of Hope Medical Center, with 120 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-01-07. Interventions recorded: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration. Conditions recorded: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma.
Linked to the drug Dronabinol because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.